The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study

Table 1 Baseline Participants information in nano-curcumin and control groups

Characteristics	Nano-curcumin group N = 22	Control group N = 22	P value
Anthropometric measurements
Gender
Female	21 (95.5%)	21 (95.5%)	0.75^a
Male	1 (4.5%)	1 (4.5%)
Age (years)	39.27 ± 2.15	41.00 ± 2.42	0.59^b
Weight (kg)	77.52 ± 2.37	74.18 ± 1.66	0.25^b
Height (cm)	161.82 ± 1.58	160.50 ± 1.53	0.55^b
BMI (kg/m2)	29.66 ± 0.86	29.03 ± 0.75	0.40^b
WC (cm)	98.18 ± 1.05	96.91 ± 1.08	0.58^b
Clinical characteristics
Onset of migraine age (year)	28.06 ± 2.53	26.14 ± 1.94	0.54^b
Headache frequency (number/week)	3.59 ± 0.38	3.23 ± 0.37	0.43^c
Duration of attacks (hours)	14.41 ± 2.45	17.55 ± 3.21	0.70^c
Severity of pain (VAS scoring 0–10)	7.45 ± 0.38	7.64 ± 0.31	0.87^c

ISSN: 1756-0500